Biofrontera To Launch Phase 3 Clinical Study Evaluating Ameluz-PDT For The Treatment Of Actinic Keratosis On The Extremities, Neck and Trunk
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled,